Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications
Authors:
- Fabrice AndreFAFabrice Andre
- Dominique GrunenwaldDGDominique Grunenwald
- Jean-Pierre PignonJPJean-Pierre Pignon
- Antoine DujonADAntoine Dujon
- Jean Louis PujolJPJean Louis Pujol
- Pierre Yves BrichonPBPierre Yves Brichon
- Laurent BrouchetLBLaurent Brouchet
- Elisabeth QuoixEQElisabeth Quoix
- Virginie WesteelVWVirginie Westeel
- Thierry Le ChevalierTCThierry Le Chevalier
- 16 August 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (16) , 2981-2989
Abstract
PURPOSE: Patients who suffer from non–small-cell lung cancer (NSCLC) with ipsilateral mediastinal lymph node involvement (N2) belong to a heterogeneous subgroup of patients. We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups. PATIENTS AND METHODS: The present study comprised 702 consecutive patients from six French centers who underwent surgical resection of N2 NSCLC. Initially, two groups of patients were defined: patients with clinical N2 (cN2) and those with minimal N2 (mN2) disease were patients in whom N2 disease was and was not detected preoperatively at computed tomographic scan, respectively. RESULTS: The median duration of follow-up was 52 months (range, 18 to 120 months). A multivariate analysis using Cox regression identified four negative prognostic factors, namely, cN2 status (P < .0001), involvement of multiple lymph node levels (L2+; P < .0001), pT3 to T4 stage (P < .0001), and no preoperative chemotherapy (P < .01). For patients treated with primary surgery, 5-year survival rates were as follows: mN2, one level involved (mN2L1, n = 244): 34%; mN2, multiple level involvement (mN2L2+, n = 78): 11%; cN2L1 (n = 118): 8%; and cN2L2+ (n = 122): 3%. When only patients with mN2L1 disease were considered, the site of lymph node involvement according to the American Thoracic Society numbering system had no prognostic significance (P = .14). Preoperative chemotherapy was associated with a better prognosis for those with cN2 (P < .0001). Five-year survival rates were 18% and 5% for cN2 patients treated with and without preoperative chemotherapy, respectively. CONCLUSION: This study has identified homogeneous N2 NSCLC prognostic subgroups and suggests different therapeutic approaches according to the subgroup profile.Keywords
This publication has 38 references indexed in Scilit:
- French phase III trial of preoperative chemotherapy (PCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC)Lung Cancer, 2000
- Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in miceBritish Journal of Cancer, 1999
- Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trialsThe Lancet, 1998
- Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.Journal of Clinical Oncology, 1998
- Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literatureLung Cancer, 1998
- Re: Stage IIIA Category of Non-Small-Cell Lung Cancer: A New ProposalJNCI: Journal of the National Cancer Institute, 1997
- Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.Journal of Clinical Oncology, 1995
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- Results of Resection in Non-Oat Cell Carcinoma of the Lung with Mediastinal Lymph Node MetastasesAnnals of Surgery, 1983